InVivoMAb Anti-Human ErbB2/Her2 Antibody (520C9) (HY286010)

Name: InVivoMAb Anti-Human ErbB2/Her2 Antibody (520C9)
Brand: abinScience
SKU: HY286010
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HY286010
Description	InVivoMAb Anti-Human CD340/ERBB2/HER2/NEU Antibody (520C9) [520C9] (HY286010) is a mouse monoclonal antibody detecting p185erbB2 in Blocking, ELISA. Suitable for Human.
Reactivité des espèces	Human
Applications	Blocking, ELISA
Espèce hôte	Mouse
Clonalité	Monoclonal
Isotype	IgG2a, kappa
ID de clone	520C9
Cible	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
Niveau d'endotoxines	< 1 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Produits associés	pH 7.4 Dilution Buffer
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P04626
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Contexte	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
Note	For research use only. Not suitable for clinical or therapeutic use.